Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases

Journal of Surgical Oncology

Volumn 113, Issue 4, 2016, Pages 449-455

  Simoneau, Eve ^a   Alanazi, Reema ^b   Alshenaifi, Jumanah ^b   Molla, Nouran ^c   Aljiffry, Murad ^d   Medkhali, Ahmad ^b   Boucher, Louis Martin ^c   Asselah, Jamil ^c   Metrakos, Peter ^a   Hassanain, Mazen ^a,c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c MCGILL UNIVERSITY   (Canada)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

chemotherapy; colorectal cancer liver metastases; hepatectomy; liver regeneration; PVE

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

ADJUVANT THERAPY; AGED; ARTIFICIAL EMBOLIZATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; COLORECTAL CANCER LIVER METASTASIS; COLORECTAL LIVER METASTASIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER HYPERTROPHY; LIVER PARENCHYMA; LIVER REGENERATION; LIVER RESECTION; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PORTAL VEIN; PORTAL VEIN EMBOLIZATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; CHEMOEMBOLIZATION; COLORECTAL TUMOR; DRUG EFFECTS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PORTAL VEIN; RETROSPECTIVE STUDIES;

EID: 84960360556     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24139     Document Type: Conference Paper

References (39)

1. Siegel R, DeSantis C, Jemal A,: Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117.
2. Mayo S, Pawlik T,: Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009; 3: 131-144.
3. Adam R, Hoti E, Bredt LC,: Evolution of neoadjuvant therapy for extended hepatic metastases-have we reached our (non-resectable) limit ? J Surg Oncol 2010; 102: 922-931.
4. Michalopoulos GK,: Liver regeneration. J Cell Physiol 2007; 213: 286-300.
5. Fausto N, Campbell JS, Riehle KJ,: Liver regeneration. Hepatology 2006; 43: S45-S53.
6. Knoefel W, Gabor I, Rehders A, et al.,: In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. Br J Surg 2012; 100: 388-394.
7. Simoneau E, Aljiffry M, Salman A, et al.,: Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) 2012; 14: 461-468.
8. Nordlinger B, Sorbye H, Glimelius B, et al.,: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215.
9. Tanaka K, Adam R, Shimada H, et al.,: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963-969.
10. Adam R, Delvart V, Pascal G, et al.,: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-658.
11. de Gramont A, Figer A, Seymour M, et al.,: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
12. Goldberg RM, Sargent DJ, Morton RF, et al.,: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
13. Hochster HS, Hart LL, Ramanathan RK, et al.,: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study. J Clin Oncol 2008; 26: 3523-3529.
14. Porschen R, Arkenau H-T, Kubicka S, et al.,: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-4223.
15. Tol J, Koopman M, Cats A, et al.,: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al.,: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
17. Bilchik AJ, Poston G, Curley SA, et al.,: Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note. J Clin Oncol 2005; 23: 9073-9078.
18. Ellis LM, Curley SA, Grothey A,: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23: 4853-4855.
19. Sturesson C, Nilsson J, Eriksson S, et al.,: Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford) 2013; 15: 646-652.
20. Sturesson C, Keussen I, Tranberg K-G,: Prolonged chemotherapy impairs liver regeneration after portal vein occlusion-An audit of 26 patients. Eur J Surg Oncol 2010; 36: 358-364.
21. Ribero D, Abdalla EK, Madoff DC, et al.,: Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94: 1386-1394.
22. Tanaka K, Kumamoto T, Matsuyama R, et al.,: Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg 2010; 14: 359-368.
23. Beal IK, Anthony S, Papadopoulou A, et al.,: Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006; 79: 473-478.
24. Dello SAWG, Kele PGS, Porte RJ, et al.,: Influence of preoperative chemotherapy on CT volumetric liver regeneration following right hemihepatectomy. World J Surg 2014; 38: 497-504.
25. Covey AM, Brown KT, Jarnagin WR, et al.,: Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008; 247: 451-455.
26. Fischer C, Melstrom LG, Arnaoutakis D, et al.,: Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg 2013; 148: 1103-1108.
27. Humar A, Kosari K, Sielaff TD, et al.,: Liver regeneration after adult living donor and deceased donor split-liver transplants. Liver Transpl 2004; 10: 374-378.
28. Nagasue N, Yukaya H, Ogawa Y, et al.,: Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg 1987; 206: 30-39.
29. Kele PG, de Boer M, van der Jagt EJ, et al.,: Early hepatic regeneration index and completeness of regeneration at 6 months after partial hepatectomy. Br J Surg 2012; 99: 1113-1119.
30. Ishak K, Baptista A, Bianchi L, et al.,: Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
31. Tanaka W, Yamanaka N, Oriyama T, et al.,: Multivariate analysis of liver regenerative capacity after hepatectomy in humans. J Hepatobiliary Pancreat Surg 1997; 4: 78-82.
32. Yamanaka N, Okamoto E, Kawamura E, et al.,: Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology 1993; 18: 79-85.
33. Strasberg SM,: Nomenclature of hepatic anatomy and resections: A review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12: 351-355.
34. Abdalla EK, Adam R, Bilchik AJ, et al.,: Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280.
35. Kesmodel SB, Ellis LM, Lin E, et al.,: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260.
36. Ribero D, Chun Y, Vauthey J,: Standardized liver volumetry for portal vein embolization. Semin intervent Radiol 2008; 25: 104-109.
37. Goéré D, Farges O, Leporrier J, et al.,: Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006; 10: 365-370.
38. Takeda D, Nitta H, Takahara T, et al.,: Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume. World J Surg Oncol 2013; 11: 65.
39. Zalinski S, Bigourdan J-M, Vauthey J-N,: [Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?]. J Chir (Paris) 2010; 147: S18-S24.